If Fluticare is rejected, it will be interesting for INNV to try and get its' stock back from Novalere.
Let's say Fluticare is approved in Q1 2017 and in general, INNV is doign well, who if anyone would be interested in buying INNV? (I doubt big pharma, because INNV really isn't pharma...) Would herbal life care about buying INNV?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.